Patient-reported outcomes from a phase 3 study of baricitinib versus placebo or adalimumab in rheumatoid arthritis: secondary analyses from the RA-BEAM study

por Keystone, Edward C, Taylor, Peter C, Tanaka, Yoshiya, Gaich, Carol, DeLozier, Amy M, Dudek, Anna, Zamora, Jorge Velasco, Cobos, Jose Arturo Covarrubias, Rooney, Terence, de Bono, Stephanie, Arora, Vipin, Linetzky, Bruno, Weinblatt, Michael E
Publicado 2017